Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015. Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment. Jan 30, 2013
Pfizer and Eli Lilly Report Strong Performance; Drug Pipelines Continue to Advance
Let's take a look at Pfizer's and Lilly's fourth-quarter reports. Dec 18, 2012
Inside the New Abbott: A Lot Like the Old Abbott But Without Humira
We take a dive inside the prospects of the “new” Abbott, which is quite a bit like the old Abbott—minus Humira. Dec 11, 2012
Inside AbbVie: A Look at a New Pharmaceutical Giant
Let's take a look at Abbott's new standalone business, AbbVie. Oct 31, 2012
5 Highly Ranked Dividend Growth Stocks
Let's take a look at 5 highly ranked dividend growth stocks. Oct 27, 2012
AstraZeneca Is Not Immune to Patent Cliff
AstraZeneca faced revenue and earnings pressure from the loss of exclusivity of Seroquel IR. Still, the firm boasts an impressive pipeline, and management reiterated its full-year earnings guidance. Aug 15, 2012
Valuentum's August Edition of Its Best Ideas Newsletter! Our Best Ideas Portfolio Hits Record High
The August edition of our Best Ideas Newsletter is now available. Jul 31, 2012
Pfizer Reports Decent Second Quarter Results; Plans to Spin Off Animal Health Business
Pfizer posted decent second-quarter results that showed strong cost containment in the face of declining sales of its blockbuster drug Lipitor. The company also announced plans to spin off its animal health business to focus on its core pharma business. We maintain our view that Pfizer is significantly underpriced. Jul 19, 2012
Our Outlook for the Market
President of Equity Research & ETF Analysis, Brian Nelson offers insight into Valuentum's outlook for the market. The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
